Literature DB >> 16154961

Different effects of adenosine A1 agonist ribavirin on amphetamine-induced total locomotor and stereotypic activities in rats.

Branka Janać1, Vesna Pesić, Sanja Peković, Ljubisav Rakić, Mirjana Stojiljković.   

Abstract

Pretreatment with a single dose of ribavirin (10, 20, and 30 mg/kg b.w., i.p.) decreased amphetamine (1.5 mg/kg b.w., i.p.)-induced total locomotor activity (distance traveled) compared to amphetamine alone, but the most significant effect was observed with 30 mg/kg dose. In contrast, total stereotypic activities (such as sniffing, self-grooming, licking, and head weaving) of these animals were unchanged. These findings demonstrate the ability of ribavirin to modulate in a different way central regulation of locomotor and stereotypic activities that in the future could have a practical application in target therapy of some movement disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16154961     DOI: 10.1196/annals.1342.048

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

1.  Design and in Vivo Characterization of A1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.

Authors:  Dilip K Tosh; Harsha Rao; Amelia Bitant; Veronica Salmaso; Philip Mannes; David I Lieberman; Kelli L Vaughan; Julie A Mattison; Amy C Rothwell; John A Auchampach; Antonella Ciancetta; Naili Liu; Zhenzhong Cui; Zhan-Guo Gao; Marc L Reitman; Oksana Gavrilova; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2019-01-03       Impact factor: 7.446

Review 2.  The Role of Adenosine Receptors in Psychostimulant Addiction.

Authors:  Inmaculada Ballesteros-Yáñez; Carlos A Castillo; Stefania Merighi; Stefania Gessi
Journal:  Front Pharmacol       Date:  2018-01-10       Impact factor: 5.810

3.  The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.

Authors:  Rami A Ballout; Dmitri Sviridov; Michael I Bukrinsky; Alan T Remaley
Journal:  FASEB J       Date:  2020-05-05       Impact factor: 5.834

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.